Ablaze Pharmaceuticals (Ablaze), a clinical-stage pharmaceutical company, announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. (Yonghe) to develop series of targeted radiopharmaceutical therapy (TRT) products. Under the agreement, Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze from pharmaceutical research and preclinical activities to clinical studies.
